Top Biomed Stock
Report Date: 06-18-2022
Symbol: OBSV - ObsEva SA
Sector:
Industry:
Top Biomed Stock Signal: OBSV
ObsEva SA (OBSV)
Chemin des Aulx 12
PLAN-LES-OUATES, GENEVE 1228
Phone: 41225521558
Website: https://www.obseva.com
CEO: Dr. Ernest Loumaye
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.